HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 400 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer June 19, 2019 EMA Recommends Extension of Therapeutic Indications for Cabozantinib April 29, 2022 Dr Ian Walker on Smoking: ‘An unequal burden, but a fixable... March 31, 2023 COVID-19 Vaccines May Be Less Effective in Some People with Cancer May 26, 2021 Load more HOT NEWS Five Questions With…Jessica, Katie, and Melanie Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In... Contraception and cancer – a look behind the headlines Cannabis, cannabinoids and cancer – the evidence so far
